Positive Top-Line Results for Xolair® Biosimilar Efficacy Study
Alvotech, Kashiv Biosciences, and Advanz Pharma announced positive topline results from a phase 3 study of AVT23 (ADL-018), a...
Exact Therapeutics Doses First Patient in Phase 2 Pancreatic Cancer Trial
EXACT Therapeutics has initiated its Phase 2 ENACT trial, evaluating Acoustic Cluster Therapy (ACT) combined with standard chemotherapy in...
Tern-601 GLP-1R Agonist Shows Promise for Obesity Treatment
Terns Pharmaceuticals announced data from a completed Phase 1 study and full enrollment of its Phase 2 FALCON trial...
IMDX Reports Strong Kidney Transplant Rejection Test Data
iMDx (Nasdaq: IMDX) announced positive results from a head-to-head study comparing its flagship digital PCR-based dd-cfDNA test kit, GraftAssureIQ,...
Sana Biotechnology: Positive Results in Type 1 Diabetes Islet Cell Transplant Study
Sana Biotechnology announced six-month follow-up results from a first-in-human study transplanting HIP-modified (hypoimmune) allogeneic islet cells (UP421) into a...
Revolutionary Daraxonrasib Wins FDA Breakthrough Therapy for Pancreatic Cancer
Revolution Medicines received Breakthrough Therapy Designation from the FDA for daraxonrasib, its RAS(ON) inhibitor, targeting previously treated metastatic pancreatic...
CUE Biopharma to Advance IND for CUE-401 in Autoimmune Disease
Cue Biopharma received positive Pre-Investigational New Drug (Pre-IND) feedback from the FDA for CUE-401, a first-in-class bispecific molecule designed...
BioVie to Present Phase 2 Sunrise-PD Trial Overview at the Advanced Therapeutics Congress
BioVie Inc. announced that a poster detailing the decentralized design and patient experience of its Phase 2 SUNRISE-PD clinical...
Inventprise’s COVID-19 Vaccine Breakthrough Published in Vaccine Journal
Inventprise, a clinical-stage vaccine company, published preclinical study results in Vaccine Journal demonstrating the potential of their bivalent SARS-CoV-2...
Actuate Therapeutics Reports Positive Phase 2 Elraglusib Trial Results in Metastatic Pancreatic Cancer
Actuate Therapeutics announced positive results from a Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) as a first-line...